SCF ENCYCLOPEDIA ENTRY

PERSISTENT INTRAHEPATIC CHOLESTASIS SEQUELAE

SCF-RDOS Registry Code: SCF-RDOS-PPD-GI-005

Disease Type Classification: Hepatobiliary Disease → Cholestatic Liver Disorder → Postpartum Persistent Cholestatic Sequelae Syndrome

Adaptive Module Activation:

• Universal Core Module
• Hepatobiliary Disease Expansion
• Gastrointestinal Disease Expansion
• Endocrine-Metabolic Expansion
• Immunohepatic Expansion
• Bile Acid Signaling Expansion
• Fibrosis and Tissue Remodeling Expansion

1. SCOPE & POSITIONING

Etiology / Classification

Persistent Intrahepatic Cholestasis Sequelae (PICS) refers to the continuation, recurrence, or long-term consequences of cholestatic dysfunction following resolution of pregnancy-associated cholestatic disease, most commonly following Intrahepatic Cholestasis of Pregnancy (ICP).

While most cases of ICP resolve within days to weeks after delivery, a subset of women develop persistent hepatobiliary abnormalities, recurrent cholestasis, chronic bile acid dysregulation, hepatocellular injury, or progressive liver disease.

Persistent sequelae may include:

• Persistent hypercholanemia
• Chronic pruritus
• Persistent liver enzyme abnormalities
• Recurrent cholestatic episodes
• Gallbladder disease
• Biliary dysfunction
• Hepatic fibrosis
• Metabolic liver disease
• Chronic hepatobiliary inflammation

SCF Classification

SCF Disease Category: Hepatobiliary Regulatory Failure Syndrome

SCF Functional Class:

Maternal Bile Acid Homeostasis Persistence Disorder

SCF Fault Tier Classification

Clinical Significance

Persistent cholestatic sequelae may signal underlying hepatobiliary vulnerability and increase the risk of future liver disease.

Potential complications include:

• Chronic cholestasis
• Recurrent intrahepatic cholestasis
• Cholelithiasis
• Cholangitis
• Hepatic fibrosis
• Cirrhosis (rare)
• Chronic pruritus
• Fat-soluble vitamin deficiencies
• Metabolic dysfunction-associated steatotic liver disease (MASLD)

SCF Domain Alignment

Primary Domains:

• Hepatic
• Biliary
• Gastrointestinal
• Metabolic

Secondary Domains:

• Immune
• Endocrine
• Fibrotic
• Mitochondrial

2. ETIOPATHOGENIC CORE

Primary Cause

Persistent Intrahepatic Cholestasis Sequelae develops through convergence of:

• Persistent bile acid dysregulation
• Hepatocellular transport dysfunction
• Canalicular secretion abnormalities
• Genetic susceptibility
• Chronic inflammatory signaling
• Fibrotic remodeling
• Metabolic-hepatic maladaptation

Key Drivers

Driver A — Bile Acid Transport Dysfunction

Persistent abnormalities may involve:

• BSEP (ABCB11)
• MDR3 (ABCB4)
• ATP8B1
• FXR signaling pathways

Result:

• Impaired bile acid clearance

Driver B — Residual Hepatocellular Injury

Following cholestatic pregnancy:

• Hepatocyte stress persists
• Canalicular transport remains impaired

Result:

• Ongoing cholestatic physiology

Driver C — Chronic Bile Acid Toxicity

Accumulation of bile acids causes:

• Oxidative stress
• Mitochondrial dysfunction
• Cellular injury

Result:

• Progressive hepatic damage

Driver D — Fibrotic Remodeling

Persistent injury activates:

• Hepatic stellate cells
• Fibrogenic pathways
• Extracellular matrix deposition

Result:

• Fibrosis development

Driver E — Metabolic-Hepatic Dysregulation

Associated abnormalities include:

• Dyslipidemia
• Insulin resistance
• MASLD susceptibility

Result:

• Long-term hepatometabolic disease risk

3. SCF FAULT ARCHITECTURE

4. PATHOGENESIS FLOW (SCF LOGIC)

Intrahepatic Cholestasis of Pregnancy

↓

Delivery

↓

Expected Cholestatic Resolution

↓

Incomplete Hepatobiliary Recovery

↓

Persistent Transport Dysfunction

↓

Bile Acid Retention

↓

Hepatocellular Stress

↓

Oxidative Injury

↓

Inflammatory Activation

↓

Fibrotic Remodeling

↓

Persistent Cholestasis

↓

Chronic Hepatobiliary Disease

5. CLINICAL SPECTRUM

6. SCF TRINITY FRAMEWORK MAPPING

Trinity Axis I — Structural Integrity

Affected Systems:

• Hepatocytes
• Bile canaliculi
• Intrahepatic biliary network

Primary Failure:

• Hepatobiliary transport architecture dysfunction

Trinity Axis II — Energetic Integrity

Affected Systems:

• Hepatic mitochondria
• Bile acid metabolic pathways
• Oxidative phosphorylation systems

Primary Failure:

• Hepatocellular bioenergetic stress

Trinity Axis III — Informational Integrity

Affected Systems:

• FXR signaling
• Bile acid sensing pathways
• Hepatic endocrine-metabolic communication

Primary Failure:

• Bile acid regulatory desynchronization

7. HEPATOBILIARY EXPANSION MODULE

Clinical Subtype Registry

Type A

Persistent Hypercholanemic Syndrome

Characteristics:

• Elevated bile acids
• Minimal structural disease

Type B

Persistent Cholestatic Hepatitis

Characteristics:

• Liver enzyme abnormalities
• Ongoing hepatocellular injury

Type C

Fibrotic Cholestatic Disease

Characteristics:

• Progressive fibrosis
• Structural remodeling

Type D

Recurrent Cholestatic Syndrome

Characteristics:

• Intermittent cholestatic flares
• Trigger-sensitive disease

Type E

Hepatometabolic Sequelae Syndrome

Characteristics:

• MASLD association
• Dyslipidemia
• Insulin resistance

8. MULTI-OMICS PATHOGENESIS MAP

9. SCF PCR THERAPEUTIC STRATEGY

PREVENTATIVE

Objectives

Prevent progression from transient cholestasis to chronic hepatobiliary disease.

Targets:

• Bile acid accumulation
• Hepatocyte injury
• Fibrotic signaling
• Metabolic dysfunction

CURATIVE

Objectives

Restore bile acid homeostasis and hepatobiliary function.

Targets:

• Cholestasis
• Transport dysfunction
• Oxidative stress
• Inflammation

Interventions:

• Hepatology-directed management
• Bile acid modulation strategies
• Nutritional optimization
• Monitoring for progressive liver disease

RESTORATIVE

Objectives

Re-establish long-term hepatobiliary resilience.

Targets:

• Canalicular transport recovery
• Mitochondrial restoration
• Fibrosis regression
• Metabolic-hepatic synchronization

Potential strategies:

• FXR-targeted therapeutic platforms
• Anti-fibrotic regenerative systems
• SCF-derived hepatobiliary restorative therapeutics
• Precision bile acid homeostasis modulation

10. CURRENT STANDARD OF CARE

Diagnostic Evaluation

Laboratory Assessment

• Serum bile acids
• ALT
• AST
• Alkaline phosphatase
• GGT
• Bilirubin
• Albumin

Imaging

• Hepatic ultrasound
• Elastography
• MRI/MRCP when indicated

Additional Evaluation

• Genetic testing in recurrent disease
• Fibrosis assessment
• Metabolic risk evaluation

Treatment

Monitoring

• Serial liver function testing
• Bile acid monitoring
• Fibrosis surveillance

Medical Management

When clinically appropriate:

• Ursodeoxycholic acid-based strategies
• Nutritional support
• Vitamin supplementation if deficiencies occur

Long-Term Care

• Hepatology follow-up
• Future pregnancy risk counseling
• Chronic liver disease surveillance

11. SCF THERAPEUTIC ENGINEERING OPPORTUNITIES

SCF Target Cluster A

Bile Acid Homeostasis Platform

Targets:

• FXR
• BSEP
• MDR3
• FGF19 signaling

SCF Target Cluster B

Hepatocyte Protection Platform

Targets:

• Oxidative stress pathways
• Mitochondrial resilience
• Cellular repair systems

SCF Target Cluster C

Anti-Fibrotic Remodeling Platform

Targets:

• Stellate cell activation
• TGF-β signaling
• ECM deposition pathways

SCF Target Cluster D

Gut-Liver Synchronization Platform

Targets:

• Microbiome-derived bile acid metabolism
• Enterohepatic circulation
• Hepatic-metabolic communication

12. TRANSLATIONAL BLUEPRINT

Diagnostic Biomarkers

Cholestatic

• Total serum bile acids
• FGF19
• C4 (7α-hydroxy-4-cholesten-3-one)

Hepatic

• ALT
• AST
• GGT
• Bilirubin

Fibrotic

• ELF score
• Hyaluronic acid
• Pro-collagen biomarkers

Metabolic

• Lipid profile
• Insulin resistance markers

Clinical Endpoints

Primary:

• Normalization of bile acid homeostasis

Secondary:

• Resolution of cholestatic symptoms
• Prevention of fibrosis progression
• Improvement in hepatic function
• Reduction of hepatometabolic risk

FDA Translational Pathway

Preclinical

↓

IND

↓

Phase I Safety

↓

Phase II Proof-of-Concept

↓

Phase III Outcomes

↓

NDA/BLA Submission

13. SCF DBI INTERPRETATION

Decentralized Biological Intelligence Failure

Cellular Layer

Hepatocytes lose precise regulation of bile acid transport and detoxification.

Tissue Layer

The hepatobiliary network remains trapped in a state of incomplete recovery and chronic stress.

Organ Layer

The liver fails to fully restore normal bile production, transport, and clearance dynamics.

System Layer

Gut-liver-metabolic communication becomes persistently dysregulated.

Whole-Organism Layer

Maternal physiologic recovery after pregnancy remains impaired by ongoing hepatobiliary dysfunction and bile acid homeostasis failure.

14. SCF LAYMAN’S SUMMARY

Persistent Intrahepatic Cholestasis Sequelae refers to ongoing liver and bile-flow problems that continue after a pregnancy complicated by Intrahepatic Cholestasis of Pregnancy (ICP).

According to the SCF model, the condition develops when the liver does not completely recover its ability to properly transport and eliminate bile acids after delivery. As bile acids accumulate, they can continue to irritate and damage liver cells, leading to chronic symptoms and, in some cases, progressive liver disease.

Common features include:

• Persistent itching
• Abnormal liver tests
• Elevated bile acid levels
• Fatigue
• Digestive discomfort
• Increased risk of gallbladder disease

Most women recover completely after ICP, but those with persistent sequelae require long-term monitoring to prevent progression toward chronic hepatobiliary disease.

SCF-RDOS INDICATION SUMMARY